IRIS
GHIA, PAOLO PROSPERO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.068
NA - Nord America 1.269
AS - Asia 1.139
SA - Sud America 19
OC - Oceania 12
AF - Africa 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 4.513
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.256
SE - Svezia 1.006
CN - Cina 601
SG - Singapore 448
IT - Italia 408
RU - Federazione Russa 315
FI - Finlandia 84
IE - Irlanda 65
DE - Germania 56
NL - Olanda 35
IN - India 33
AE - Emirati Arabi Uniti 20
BR - Brasile 17
GB - Regno Unito 17
FR - Francia 16
AU - Australia 11
CH - Svizzera 11
BE - Belgio 9
CA - Canada 9
ES - Italia 8
IR - Iran 6
HK - Hong Kong 5
CZ - Repubblica Ceca 4
DK - Danimarca 4
GR - Grecia 4
HU - Ungheria 4
MV - Maldive 4
PH - Filippine 4
PL - Polonia 4
TW - Taiwan 4
UA - Ucraina 4
EG - Egitto 3
KZ - Kazakistan 3
NO - Norvegia 3
PA - Panama 3
PK - Pakistan 3
AR - Argentina 2
EU - Europa 2
IL - Israele 2
IQ - Iraq 2
LT - Lituania 2
MK - Macedonia 2
AT - Austria 1
BG - Bulgaria 1
FJ - Figi 1
GA - Gabon 1
JP - Giappone 1
MX - Messico 1
MY - Malesia 1
OM - Oman 1
PT - Portogallo 1
RO - Romania 1
RS - Serbia 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
VN - Vietnam 1
Totale 4.513
Salva come PNG Salva come JPEG
Città #
Shanghai 380
Lawrence 328
Princeton 328
Singapore 275
Ashburn 192
Milan 186
Moscow 136
Helsinki 72
New York 69
Dublin 64
Boardman 41
Dallas 30
Rome 29
Guangzhou 23
Dubai 20
Seattle 18
Los Angeles 16
Pune 16
Ridgewood 14
Beijing 13
Lappeenranta 11
Zurich 11
Dronten 10
Shenzhen 10
Wuxi 9
Sydney 8
Washington 8
Hangzhou 7
Chennai 6
Meppel 6
Mol 6
Nuneaton 6
Borås 5
Cesano Boscone 5
Kassel 5
Taranto 5
Turin 5
Athens 4
Buffalo 4
Ferrara 4
London 4
Male 4
Mountain View 4
Paris 4
Prague 4
Redwood City 4
Toronto 4
Warsaw 4
Zhengzhou 4
Bari 3
Brussels 3
Cagliari 3
Cairo 3
Dasmariñas 3
Florence 3
Fontanellato 3
Genoa 3
Hong Kong 3
Jiaxing 3
Munich 3
Naples 3
Panama City 3
Portland 3
Quanzhou 3
Reggio Emilia 3
Signa 3
Tianjin 3
Verona 3
Xi'an 3
Amsterdam 2
Andria 2
Astana 2
Baghdad 2
Banqiao 2
Barcelona 2
Bergen 2
Berlin 2
Budapest 2
Caerano di San Marco 2
Catania 2
Changsha 2
Cormano 2
Creon 2
Duncan 2
Fort Worth 2
Foshan 2
Frankfurt am Main 2
Freiburg im Breisgau 2
Gorle 2
Gujranwala 2
Hanover 2
Hefei 2
Hyderabad 2
Kaifeng 2
Las Vegas 2
Linyi 2
Madrid 2
Majadahonda 2
Melbourne 2
Mirano 2
Totale 2.543
Salva come PNG Salva come JPEG
Nome #
Rugarli. Medicina interna sistematica 93
ZAP-70 is expressed by normal and malignant human B-cell subsets of different maturational stage 47
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial 39
ZAP-70 expression is associated with increased risk of autoimmune cytopenias in CLL patients 31
Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia 28
Targeting the LYN/HS1 signaling axis in chronic lymphocytic leukemia 26
3D co-culture model of chronic lymphocytic leukemia bone marrow microenvironment predicts patient-specific response to mobilizing agents 25
Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study 25
A retinoic acid-dependent stroma-leukemia crosstalk promotes chronic lymphocytic leukemia progression 24
IκBε deficiency accelerates disease development in chronic lymphocytic leukemia 23
Chronic lymphocytic leukemia 23
3D Bioprinting Allows the Establishment of Long-Term 3D Culture Model for Chronic Lymphocytic Leukemia Cells 23
Are we finally getting personal? Moving towards a personalized approach in chronic lymphocytic leukemia 23
BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib 22
B-Cell Clones as Early Markers for Chronic Lymphocytic Leukemia 22
A novel molecular complex expressed on immature B cells: A possible role in T cell-independent B cell development 22
Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications 22
Inhibition of chronic lymphocytic leukemia progression by full-length chromogranin A and its N-terminal fragment in mouse models 22
Pathogen-specific B-cell receptors drive chronic lymphocytic leukemia by light-chain-dependent cross-reaction with autoantigens 22
In vitro growth of human multiple myeloma: implications for biology and therapy 21
A novel Rag2(-/-)gamma(-/-)(c)-xenograft model of human CLL 21
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 21
Bone Marrow Histopathology in the Diagnostic Evaluation of Splenic Marginal-zone and Splenic Diffuse Red Pulp Small B-cell Lymphoma: A Reliable Substitute for Spleen Histopathology? 21
CLL-137 SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib Versus Bendamustine + Rituximab (BR) in Patients With Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/ SLL) 21
COVID-19 and Chronic Lymphocytic Leukemia: Where We Stand Now 20
Functional differences between IgM and IgD signaling in chronic lymphocytic leukemia 20
HIF-1α regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment 20
A woman and her canary: a tale of chlamydiae and lymphomas 20
A complementary role of multiparameter flow-cytometry and high-throughput sequencing for minimal residual disease (MRD) detection in chronic lymphocytic leukemia (CLL): An european research initiative on CLL (ERIC) study 20
Clonal B-cell lymphocytosis: a new member? 20
A novel ex vivo high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia 20
EZN-2208 treatment suppresses chronic lymphocytic leukaemia by interfering with environmental protection and increases response to fludarabine 20
HIGHER ORDER IMMUNOGLOBULIN REPERTOIRE RESTRICTIONS IN CLL: THE ILLUSTRATIVE CASE OF STEREOTYPED SUBSETS #2 AND #169 20
Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results 20
ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) 20
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study 20
Assessing Patients' Knowledge on Chronic Lymphocytic Leukemia: Validation of the ERIC CLL Knowledge Questionnaire in Greece 20
Prognostic relevance of MYD88 mutations in CLL: the jury is still out 19
Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases 19
ZAP-70 expression, as detected by immunohistochemistry on bone marrow biopsies from early-phase CLL patients, is a strong adverse prognostic factor 19
Monoclonal B-cell lymphocytosis: right track or red herring? 19
A look into the future: can minimal residual disease guide therapy and predict prognosis in chronic lymphocytic leukemia? 19
Calreticulin as a novel B-cell receptor antigen in chronic lymphocytic leukemia 19
The inhibitory receptor toll interleukin-1R 8 (TIR8/IL-1R8/SIGIRR) is downregulated in chronic lymphocytic leukemia 19
Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia 19
A new life for rituximab? 19
T-Cell Dynamics in Chronic Lymphocytic Leukemia under Different Treatment Modalities 19
null 19
Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis 19
PYK2 is overexpressed in chronic lymphocytic leukaemia: A potential new therapeutic target 18
Longitudinal analysis of T cell receptor repertoires reveals shared patterns of antigen-specific response to SARS-CoV-2 infection 18
Monoclonal CD5(+) and CD5(-) B-lymphocyte expansions are frequent in the peripheral blood of the elderly 18
Lack of TIR8/SIGIRR triggers progression of chronic lymphocytic leukemia in mouse models 18
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia 18
A screening study of Chlamydia psittaci infection in 172 cases of nodal and extranodal non-hodgkin lymphomas 18
Distinct Innate Immunity Pathways to Activation and Tolerance in Subgroups of Chronic Lymphocytic Leukemia with Distinct Immunoglobulin Receptors. 18
In Vitro Sensitivity of CLL Cells to Fludarabine May Be Modulated by the Stimulation of Toll-like Receptors 18
V delta 1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid 18
BTK Inhibition Impairs the Innate Response Against Fungal Infection in Patients With Chronic Lymphocytic Leukemia 18
Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL 18
CD4+T cells sustain aggressive chronic lymphocytic leukemia in Em- TCL1 mice through a CD40L-independent mechanism 18
Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature 17
Anti-CD20 rechallenge with ofatumumab in relapsed/refractory splenic marginal zone lymphoma: the MORE trial 17
Is good clinical practice becoming poor clinical care? 17
MINIMAL RESIDUAL DISEASE-DRIVEN TREATMENT INTENSIFICATION WITH SEQUENTIAL ADDITION OF IBRUTINIB TO VENETOCLAX IN R/R CLL 17
In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor 17
KAP1 regulates gene networks controlling mouse B-lymphoid cell differentiation and function 17
Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study 17
Targeting B-cell anergy in chronic lymphocytic leukemia. 17
General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL. 17
ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia—update on methodological approaches and results interpretation 17
null 17
Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia 17
A single-tube multiplex method for monitoring mutations in cysteine 481 of Bruton Tyrosine Kinase (BTK) gene in chronic lymphocytic leukemia patients treated with ibrutinib 17
CXCL13 (BCA-1) is produced by follicular lymphoma cells: role in the accumulation of malignant B cells 16
A frequent EcoRI polymorphism in the bcl-2 gene 16
Cytokines involved in the progression of multiple myeloma 16
Xenograft models of chronic lymphocytic leukemia: problems, pitfalls and future directions. 16
A different ontogenesis for chronic lymphocytic leukemia cases carrying stereotyped antigen receptors: molecular and computational evidence 16
B cell anergy modulated by TLR1/2 and the MIR-17∼92 cluster underlies the indolent clinical course of chronic lymphocytic leukemia stereotyped subset #4 16
MicroRNA and proliferation control in chronic lymphocytic leukemia: functional relationship between miR-221/222 cluster and p27 16
Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project 16
Reply to "CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report" Analysis of six hematological centers in Lombardy : On behalf of CLL commission of Lombardy Hematology Network (REL) 16
Relevance of Minimal Residual Disease in the Era of Targeted Agents 16
Establishment and Characterization of PCL12, a Novel CD5+ Chronic Lymphocytic Leukaemia Cell Line 16
Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1–2 study 16
Profiling the Genomic Landscape at the Early Stages of CLL: Low Genomic Complexity and Paucity of Driver Mutations in MBL and Indolent CLL 16
Dimethyl itaconate selectively targets inflammatory and metabolic pathways in chronic lymphocytic leukemia 15
CLL-like monoclonal B-cell lymphocytosis: are we all bound to have it? 15
Monoclonal B lymphocytosis in the general population 15
Monoclonal B cell lymphocytosis and "in situ" lymphoma 15
MBL Versus CLL How Important Is the Distinction? 15
Antigen selection in B-cell lymphomas-Tracing the evidence 15
Reprogramming cell death: BCL2 family inhibition in hematological malignancies 15
Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2 15
Chronic lymphocytic leukaemia 15
The phase 3 DUO trial: Duvelisib vs ofatumumab in relapsed and refractory CLL/SLL 15
Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials 15
Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes 15
Interleukin-1 receptor-associated kinase 4 inhibitor interrupts toll-like receptor signalling and sensitizes chronic lymphocytic leukaemia cells to apoptosis 15
Totale 1.995
Salva come PNG Salva come JPEG
Categoria #
all - tutte 89.641
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 89.641
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202151 0 0 0 0 22 25 3 0 1 0 0 0
2021/2022193 0 0 0 79 28 6 17 17 16 9 6 15
2022/20231.988 758 410 124 3 39 254 71 111 85 32 34 67
2023/2024903 42 58 49 182 68 127 22 59 4 27 87 178
2024/20251.551 694 112 102 154 141 348 0 0 0 0 0 0
Totale 4.893